Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Litifilimab in Cutaneous Lupus Erythematosus
NCT06044337Phase 3Enrolling by invitation
- Sponsor
- Biogen
- Start
- Oct 2023
- Primary completion
- Jun 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of litifilimab in subacute cutaneous lupus erythematosus (SCLE), Chronic Cutaneous Lupus Erythematosus (CCLE), sponsored by Biogen. Started Oct 2023; status: enrolling by invitation.
02
Drugs
litifilimab
03
Conditions
subacute cutaneous lupus erythematosus (SCLE)Chronic Cutaneous Lupus Erythematosus (CCLE)
Beyond the preview
Go deeper on NCT06044337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044337.